Cargando…
Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection
Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2...
Autores principales: | Abayasingam, Arunasingam, Balachandran, Harikrishnan, Agapiou, David, Hammoud, Mohamed, Rodrigo, Chaturaka, Keoshkerian, Elizabeth, Li, Hui, Brasher, Nicholas A., Christ, Daniel, Rouet, Romain, Burnet, Deborah, Grubor-Bauk, Branka, Rawlinson, William, Turville, Stuart, Aggarwal, Anupriya, Stella, Alberto Ospina, Fichter, Christina, Brilot, Fabienne, Mina, Michael, Post, Jeffrey J., Hudson, Bernard, Gilroy, Nicky, Dwyer, Dominic, Sasson, Sarah C., Tea, Fiona, Pilli, Deepti, Kelleher, Anthony, Tedla, Nicodemus, Lloyd, Andrew R., Martinello, Marianne, Bull, Rowena A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955929/ https://www.ncbi.nlm.nih.gov/pubmed/33748788 http://dx.doi.org/10.1016/j.xcrm.2021.100228 |
Ejemplares similares
-
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses
por: Balachandran, Harikrishnan, et al.
Publicado: (2022) -
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
por: Garcia-Valtanen, Pablo, et al.
Publicado: (2022) -
High activation levels maintained in receptor‐binding domain–specific memory B cells in people with severe coronavirus disease 2019
por: Gupta, Money, et al.
Publicado: (2022) -
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
por: Rouet, Romain, et al.
Publicado: (2021) -
Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1
por: Wijesundara, Danushka K., et al.
Publicado: (2017)